Alkermes (ALKS) Long-Term Deferred Tax (2011 - 2026)
Alkermes' (ALKS) quarterly Long-Term Deferred Tax came in at $134.8 million in Q1 2026, down 11.39% year-on-year from $152.1 million in Q1 2025, and up 7.15% on a QoQ basis from $125.8 million in Q4 2025.
Alkermes (ALKS) Long-Term Deferred Tax (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has 16 years of Long-Term Deferred Tax data on file, last reported at $134.8 million in Q1 2026.
- On a quarterly basis, Long-Term Deferred Tax fell 11.39% year-over-year to $134.8 million in Q1 2026; TTM through Mar 2026 was $134.8 million, a 11.39% decrease from a year earlier, with the FY2025 full-year figure at $125.8 million, down 18.74% from the prior year.
- Long-Term Deferred Tax for Q1 2026 stood at $134.8 million, up from $125.8 million in the prior quarter.
- Over the last five years, Long-Term Deferred Tax for ALKS reached as high as $195.9 million in Q4 2023 and fell as low as $112.5 million in Q1 2022.
- Historically, Long-Term Deferred Tax has averaged $147.9 million across 5 years, with a median of $152.1 million in 2025.
- Across the five-year window, Long-Term Deferred Tax surged 70.97% in 2023 and retreated 20.96% in 2024, its largest moves.
- Year by year, Long-Term Deferred Tax stood at $114.6 million in 2022, then jumped by 70.97% to $195.9 million in 2023, then declined by 20.96% to $154.8 million in 2024, then fell by 18.74% to $125.8 million in 2025, then gained by 7.15% to $134.8 million in 2026.
- Per Business Quant data, the three most recent Long-Term Deferred Tax figures were $134.8 million in Q1 2026, $125.8 million in Q4 2025, and $130.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 134.81 Mn |
| Dec 31, 2025 | 125.82 Mn |
| Sep 30, 2025 | 130.34 Mn |
| Jun 30, 2025 | 155.53 Mn |
| Mar 31, 2025 | 152.14 Mn |
| Dec 31, 2024 | 154.84 Mn |
| Sep 30, 2024 | 159.96 Mn |
| Jun 30, 2024 | 167.38 Mn |
| Mar 31, 2024 | 182.54 Mn |
| Dec 31, 2023 | 195.89 Mn |
| Sep 30, 2023 | 162.18 Mn |
| Jun 30, 2023 | 153.15 Mn |
| Mar 31, 2023 | 151.23 Mn |
| Dec 31, 2022 | 114.57 Mn |
| Sep 30, 2022 | 137.15 Mn |
| Jun 30, 2022 | 123.70 Mn |
| Mar 31, 2022 | 112.52 Mn |
| Dec 31, 2021 | 81.83 Mn |
| Sep 30, 2021 | 84.50 Mn |
| Jun 30, 2021 | 75.64 Mn |